MUNICH--(BUSINESS WIRE)--Evotec AG / Key word(s): Miscellaneous EVOTEC'S ACADEMIC BRIDGE LAB282 WITH OXFORD UNIVERSITY CELEBRATING ONE YEAR OF IMPACT
11.12.2017 / 07:31 The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
* The £ 13 m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation
Hamburg, Germany, 11 December 2017:
Evotec AG (Frankfurt Stock
Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that LAB282,
the £ 13 m drug discovery partnership between Oxford University, Oxford
Sciences Innovation and Evotec, is celebrating its first year of
operation after successfully accelerating 12 drug discovery and
development projects at the University.
In its recent fourth and
latest round of awards, LAB282 backed the following Oxford projects:
* Validation of novel targets for myelofibrosis, a severe bone marrow disorder.
* Development of glucosidase II interface inhibitors; towards a novel class of broad-spectrum antivirals.
* Discovery of potent inhibitors to DarG antitoxins as a first-in-class anti-microbial concept.
* Advancing the development of evasins, a novel class of chemokine-traps to treat inflammatory disorders.
The LAB282 approach is an innovative approach to combining critical translational funding and focused expertise for early-stage projects that have demonstrated commercial promise and can be accelerated towards the market. Started in Oxford, the LAB282 model has now been exported to Canada in a partnership between Evotec and MaRS Innovation, and Evotec plans to unveil similar partnerships in the coming months.
A highly experienced Expert-in-Residence from Evotec works closely with Oxford academics to assess life sciences projects for their commercial potential. Once selected, Evotec continues to work closely with researchers to develop their ideas, providing essential technological validation, while leveraging the resources of Oxford Sciences Innovation, the £ 600 m university venture fund manager for the University.
Thomas Hanke, Expert-in-Residence at Evotec, said: "The first year of LAB282 has been a smooth integration into the Oxford ecosystem, generating an unprecedented number of projects compared to other virtual life sciences accelerators. The success to date speaks both to the quality of Oxford research and the Oxford/Evotec partnership."
Adam Stoten, Chief Operating Officer at Oxford University Innovation, added: "We've seen an explosion of innovative ideas and companies from the University in the past couple of years. The success so far of LAB282 mirrors the progress made within the wider Oxford tech cluster, and should provide a pipeline of new, commercially validated therapeutic candidates to ensure that the Oxford Boom continues for many years to come."
Andrew McLean, Principal at Oxford Sciences Innovation, added: "LAB282's ability to find and scale ideas in the University underlines what can be accomplished by bringing together the technical expertise of Evotec, the scientific strength of the University, and the resources of the world's largest university fund aimed at a single institution. We expect that many of the projects will evolve into companies that will ensure that revolutionary science is translated to medicines that treat human disease."
About Oxford University Innovation
Oxford University Innovation
supports innovation activities across all University Divisions, managing
technology transfer and consulting activities, and providing an
innovation management service to clients around the world.
We
provide access to technology from Oxford researchers through
intellectual property licensing, spinout company formation and material
sales, and to academic expertise through our Consulting Services team.
The New Venture Support & Funding team supports investors or donors with
an interest in early-stage ventures, and manages the Oxford Angels
Network. Our Startup Incubator supports members and ex-members of the
University who wish to start or grow entrepreneur-driven ventures that
are not University spinouts. Oxford University Innovation is the highest
university patent filer in the UK and is ranked 1st in the UK for
university spinouts, having created over 160 new companies since 1988.
In the last reported financial year we completed more than 45 licenses
and consulting agreements every month. Oxentia, our innovation
management consultancy, works with university, government and industrial
clients from offices around the world.
For updates on innovations
from Oxford, follow Oxford University Innovation on LinkedIn and Twitter
or subscribe at http://innovation.ox.ac.uk/about/contact-us/#enquiry.
About Evotec AG
Evotec is a drug discovery alliance and development
partnership company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies,
academics, patient advocacy groups and venture capitalists. We operate
worldwide providing the highest quality stand-alone and integrated drug
discovery solutions, covering all activities from target-to-clinic to
meet the industry's need for innovation and efficiency in drug discovery
(EVT Execute). The Company has established a unique position by
assembling top-class scientific experts and integrating state-of-the-art
technologies as well as substantial experience and expertise in key
therapeutic areas including neuroscience, diabetes and complications of
diabetes, pain and inflammation, oncology and infectious diseases. On
this basis, Evotec has built a broad and deep pipeline of more than 80
partnered product opportunities at clinical, pre-clinical and discovery
stages (EVT Innovate). Evotec has established multiple long-term
discovery alliances with partners including Bayer, CHDI, Sanofi or UCB
and development partnerships with e.g. with Sanofi in the field of
diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the
field of neurodegenerative diseases. For additional information please
go to www.evotec.com
and follow us on Twitter @EvotecAG.
FORWARD LOOKING STATEMENTS
Information set forth in this press
release contains forward-looking statements, which involve a number of
risks and uncertainties. The forward-looking statements contained herein
represent the judgement of Evotec as of the date of this press release.
Such forward-looking statements are neither promises nor guarantees, but
are subject to a variety of risks and uncertainties, many of which are
beyond our control, and which could cause actual results to differ
materially from those contemplated in these forward-looking statements.
We expressly disclaim any obligation or undertaking to release publicly
any updates or revisions to any such statements to reflect any change in
our expectations or any change in events, conditions or circumstances on
which any such statement is based.
---------------------------------------------------------------------------
Language: English Company: Evotec AG Manfred Eigen Campus / Essener Bogen 7 22419 Hamburg Germany Phone: +49 (0)40 560 81-0 Fax: +49 (0)40 560 81-222 E-mail: info@evotec.com Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
637471 11.12.2017